Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Marketwired

01:51 EDT 21st April 2018 | BioPortfolio

Here are the most relevant search results for "Marketwired" found in our extensive news archives from over 250 global news sources.

More Information about Marketwired on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Marketwired for you to read. Along with our medical data and news we also list Marketwired Clinical Trials, which are updated daily. BioPortfolio also has a large database of Marketwired Companies for you to search.

Showing News Articles 1–25 of 10,000+ from Marketwired

Wednesday 18th April 2018

CTD Holdings Finalizes Cooperative Agreement for Alzheimer's Disease Research Program

ALACHUA, FL--(Marketwired - April 19, 2018) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has finalized a cooperative research agreement with Kerwin Research Center, LLC to explore the use of cyclodextrins in the treatment of Alzheimer's dise...

Tuesday 17th April 2018

Oncolytics Biotech(R) Demonstrates Positive Data in Two Posters at AACR Annual Meeting 2018

CALGARY, AB and SAN DIEGO, CA--(Marketwired - April 18, 2018) - - Preclinical models proved pelareorep increased PD-L1 expression in microsatellite stable (MSS) colorectal cancer cells (CRC) - - Demonstrated efficacy of pelareorep and anti-PD1 agent combination - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-...

Monday 16th April 2018

Oncolytics Biotech(R) Announces Management Change

CALGARY, AB and SAN DIEGO, CA--(Marketwired - April 17, 2018) - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced that Andres Gutierrez, Chief Medical Officer at Oncolytics, will be leaving to pursue other opportunities, effective April 23, 2018. "Doct...

Wednesday 11th April 2018

Tetra Bio-Pharma Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018

OTTAWA, ONTARIO -- (Marketwired) -- 04/12/18 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQB: TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization. Natural health products and OTC medications The authorization from the Office of...

Monday 9th April 2018

VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101

SOUTH SAN FRANCISCO, CA--(Marketwired - April 10, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the European Patent Office has issued a Notice of Intention to grant a patent related to certain methods of production for AV-101, the Co...

Tetra Bio-Pharma Announces the appointment of Gregory Drohan to its board of directors

OTTAWA, ONTARIO -- (Marketwired) -- 04/10/18 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it has appointed Gregory Drohan to its board of directors effective April 10, 2018. The company will nominate Mr. Drohan for election at Tetra's 2018 Annual Meeting of Sharehol...

Milestone Scientific Announces Appointment of Eric Gilbert as Vice President of US Sales

LIVINGSTON, NJ--(Marketwired - April 10, 2018) - Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, today announced the appointment of Eric W. Gilbert as Vice President of US Sales. Eric Gilbert brings extensive experience in medical instruments sales, including extensive experience w...

Oncolytics Biotech(R) Presents Positive REOLYSIN(R) Data in Combination with Keytruda and anti-CD73 at International Oncolytic Virus Conference 2018

CALGARY, AB and SAN DIEGO, CA--(Marketwired - April 10, 2018) - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced that a poster highlighting the effectiveness of pelareorep in combination with Keytruda® and/or an anti-CD73 immunotherapy in prostate can...

Sunday 8th April 2018

Cerecor Appoints Simon Pedder to its Board of Directors

BALTIMORE, MD--(Marketwired - April 09, 2018) - Cerecor, Inc. (NASDAQ: CERC), today announced that Simon C. Pedder, Ph.D. has been appointed to its Board of Directors. "We are delighted to welcome Dr. Pedder to our Board." said Dr. Uli Hacksell, Chairman of the Board of Cerecor, "With his experience in all stages of drug development and collaborating with the FDA on several products leading to a...

Wednesday 4th April 2018

Relevium Targets 83 Million Unique Monthly Visitors and 26 Countries Through European Expansion of Bioganix(R)

MONTREAL, QUEBEC -- (Marketwired) -- 04/05/18 -- Relevium Technologies Inc. (TSX VENTURE: RLV)(OTCQB: RLLVF)(FRANKFURT: 6BX) (the "Company" or "Relevium"), is pleased to announce that it has started the process of establishing European presence for the new Bioganix® brand in partnership with several online partners, including Amazon. Management will be doing an initial launch of eight best selli...

Advanzeon Solutions, Inc.'s Wholly-Owned Subsidiary, Pharmacy Value Management Solutions, Inc., Enters Into Agreement With Interstate Specialty Marketing, Inc.

TAMPA, FL--(Marketwired - April 05, 2018) - Advanzeon Solutions, Inc. (OTCBB: CHCR) ("Advanzeon") announced today that, through its wholly-owned subsidiary, Pharmacy Value Management Solutions, Inc. ("PVMS") (collectively, the "Company"), it has entered into an Agreement with Interstate Specialty Marketing, Inc. ("ISM"). Founded in 1983, ISM began as a traditional life insurance marketing company...

Sapience Therapeutics Enters into Drug Discovery Pact with the University of Bath

HARRISON, NY--(Marketwired - April 05, 2018) - Sapience Therapeutics, Inc., a biotechnology company focused on discovering and developing peptide therapeutics to address difficult to treat oncology indications, announced today that it has entered into a research collaboration agreement with the University of Bath to discover new therapeutic agents. "We are pleased to be collaborating with Dr. Jod...

VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder

SOUTH SAN FRANCISCO, CA--(Marketwired - April 05, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the initiation of ELEVATE, the Company's double-blind, placebo-controlled Phase 2 clinical study to evaluate the efficacy and safety of A...

NanoVibronix Announces Instrumed Surgical as its Exclusive Canadian Distributor for UroShield(TM)

ELMSFORD, NY--(Marketwired - April 05, 2018) - NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has signed Instrumed Surgical of Mississauga, Ontario, Canada as its exclusive distributor for UroShield™ products in the Canada. Instrumed Surgical is a privately held ...

Tuesday 3rd April 2018

Oncolytics Biotech(R) to Present at the MicroCap Conference

CALGARY, AB and SAN DIEGO, CA--(Marketwired - April 04, 2018) - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced that it will be presenting at the MicroCap Conference, being held at the Essex House in New York City on April 9 - 10, 2018. The Co...

ORYZON receives approval to start ETHERAL: a Phase IIa clinical trial in Alzheimer's Disease with ORY-2001

MADRID, SPAIN and CAMBRIDGE, MA--(Marketwired - April 04, 2018) - Oryzon Genomics (ISIN Code: ES0167733015) (MAD: ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that it has received approval of a Clinical Trial Application (CTA), the European IND equivalent, from the Spanish Drug Ag...

Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial

HOUSTON, TX--(Marketwired - April 04, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that patients have successfully begun trea...

Tetra Bio-Pharma Initiates Enrolment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study

OTTAWA, ONTARIO -- (Marketwired) -- 04/04/18 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the initiation of screening and enrolment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain. Tetra authorized the initiation of the patient enrolment activities at its main cli...

Monday 2nd April 2018

Tetra Bio-Pharma Names Guy Chamberland as Interim CEO

OTTAWA, ONTARIO -- (Marketwired) -- 04/03/18 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment is effective immediately. Dr. Chamberland has been Chief Scientific Officer & Regulatory Affairs of Tetra...

Relevium Announces All-Time Record High of Units Sales for Bioganix(R) in March

MONTREAL, QUEBEC -- (Marketwired) -- 04/03/18 -- Relevium Technologies Inc. (TSX VENTURE: RLV)(OTCQB: RLLVF)(FRANKFURT: 6BX) (the "Company" or "Relevium"), is pleased to report an all-time record high in unit sales for the month of March 2018. The reported record high of 16,549 units, which was achieved in a seasonally low period, reflects increased online demand for the Bioganix® established p...

Milestone Scientific Reports 46.9% Increase in Sales for the Fourth Quarter of 2017

LIVINGSTON, NJ--(Marketwired - April 03, 2018) - Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2017. Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, c...

Sunday 1st April 2018

Immune Pharmaceuticals Announces 2017 Financial Results

ENGLEWOOD CLIFFS, NJ--(Marketwired - April 02, 2018) - Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) ("Immune" or the "Company"), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the year and quarter ended December 31, 2017. Elliot Maza, President and CEO of Immune, commented, "We made ...

NeoGenomics Schedules its First Quarter Earnings Release for May 1, 2018

FT. MYERS, FL--(Marketwired - April 02, 2018) - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services,announced today that it plans to release its first quarter 2018 financial results on Tuesday, May 1, 2018. The Company has scheduled a web-cast and conference call to discuss their first quarter results on Tuesday, May 1, 2018 at 8:30 AM EDT. Interested i...

Milestone Scientific Schedules 2017 Year-End Earnings Conference Call

LIVINGSTON, NJ --(Marketwired - April 02, 2018) - Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it will host a conference call at 4:30 PM Eastern Time on Tuesday, April 3, 2018 to discuss the Company's financial results for the full year ending Decemb...

Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

BALTIMORE, MD--(Marketwired - April 02, 2018) - Cerecor Inc. (NASDAQ: CERC) today announced financial results for the fourth quarter and full year 2017. Net Revenues for the year ended 2017 were $27.8 million. As of December 31, 2017, the Company had $43.1 million in total assets including cash and cash equivalents of $2.5 million, accounts receivable of $3.3 million, and escrowed receivable of $3...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks